826 related articles for article (PubMed ID: 33945847)
1. Modeling pancreatic cancer in mice for experimental therapeutics.
Mallya K; Gautam SK; Aithal A; Batra SK; Jain M
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188554. PubMed ID: 33945847
[TBL] [Abstract][Full Text] [Related]
2. Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues.
Aichler M; Seiler C; Tost M; Siveke J; Mazur PK; Da Silva-Buttkus P; Bartsch DK; Langer P; Chiblak S; Dürr A; Höfler H; Klöppel G; Müller-Decker K; Brielmeier M; Esposito I
J Pathol; 2012 Apr; 226(5):723-34. PubMed ID: 21984419
[TBL] [Abstract][Full Text] [Related]
3. Genetic Mutations of Pancreatic Cancer and Genetically Engineered Mouse Models.
Saiki Y; Jiang C; Ohmuraya M; Furukawa T
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008235
[TBL] [Abstract][Full Text] [Related]
4. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
5. Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology.
Mazur PK; Siveke JT
Gut; 2012 Oct; 61(10):1488-500. PubMed ID: 21873467
[TBL] [Abstract][Full Text] [Related]
6. Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression.
Kaneda MM; Cappello P; Nguyen AV; Ralainirina N; Hardamon CR; Foubert P; Schmid MC; Sun P; Mose E; Bouvet M; Lowy AM; Valasek MA; Sasik R; Novelli F; Hirsch E; Varner JA
Cancer Discov; 2016 Aug; 6(8):870-85. PubMed ID: 27179037
[TBL] [Abstract][Full Text] [Related]
7. Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models.
Mahajan UM; Li Q; Alnatsha A; Maas J; Orth M; Maier SH; Peterhansl J; Regel I; Sendler M; Wagh PR; Mishra N; Xue Y; Allawadhi P; Beyer G; Kühn JP; Marshall T; Appel B; Lämmerhirt F; Belka C; Müller S; Weiss FU; Lauber K; Lerch MM; Mayerle J
Gastroenterology; 2021 Sep; 161(3):996-1010.e1. PubMed ID: 34097885
[TBL] [Abstract][Full Text] [Related]
8. Precise and efficient silencing of mutant Kras
Jiang W; Li H; Liu X; Zhang J; Zhang W; Li T; Liu L; Yu X
Theranostics; 2020; 10(25):11507-11519. PubMed ID: 33052229
[No Abstract] [Full Text] [Related]
9. Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment.
Huang Y; Nahar S; Nakagawa A; Fernandez-Barrena MG; Mertz JA; Bryant BM; Adams CE; Mino-Kenudson M; Von Alt KN; Chang K; Conery AR; Hatton C; Sims RJ; Fernandez-Zapico ME; Wang X; Lillemoe KD; Fernández-Del Castillo C; Warshaw AL; Thayer SP; Liss AS
Clin Cancer Res; 2016 Aug; 22(16):4259-70. PubMed ID: 27169995
[TBL] [Abstract][Full Text] [Related]
10. Animal Models of Gastrointestinal and Liver Diseases. The difficulty of animal modeling of pancreatic cancer for preclinical evaluation of therapeutics.
Logsdon CD; Arumugam T; Ramachandran V
Am J Physiol Gastrointest Liver Physiol; 2015 Sep; 309(5):G283-91. PubMed ID: 26159697
[TBL] [Abstract][Full Text] [Related]
11. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma.
Ijichi H; Chytil A; Gorska AE; Aakre ME; Bierie B; Tada M; Mohri D; Miyabayashi K; Asaoka Y; Maeda S; Ikenoue T; Tateishi K; Wright CV; Koike K; Omata M; Moses HL
J Clin Invest; 2011 Oct; 121(10):4106-17. PubMed ID: 21926469
[TBL] [Abstract][Full Text] [Related]
13. Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma.
Avan A; Caretti V; Funel N; Galvani E; Maftouh M; Honeywell RJ; Lagerweij T; Van Tellingen O; Campani D; Fuchs D; Verheul HM; Schuurhuis GJ; Boggi U; Peters GJ; Würdinger T; Giovannetti E
Cancer Res; 2013 Nov; 73(22):6745-56. PubMed ID: 24085787
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia and pancreatic ductal adenocarcinoma.
Yamasaki A; Yanai K; Onishi H
Cancer Lett; 2020 Aug; 484():9-15. PubMed ID: 32380129
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
16. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
[TBL] [Abstract][Full Text] [Related]
17. Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment.
Gomez-Chou SB; Swidnicka-Siergiejko AK; Badi N; Chavez-Tomar M; Lesinski GB; Bekaii-Saab T; Farren MR; Mace TA; Schmidt C; Liu Y; Deng D; Hwang RF; Zhou L; Moore T; Chatterjee D; Wang H; Leng X; Arlinghaus RB; Logsdon CD; Cruz-Monserrate Z
Cancer Res; 2017 May; 77(10):2647-2660. PubMed ID: 28249896
[TBL] [Abstract][Full Text] [Related]
18. Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens.
Walters DM; Stokes JB; Adair SJ; Stelow EB; Borgman CA; Lowrey BT; Xin W; Blais EM; Lee JK; Papin JA; Parsons JT; Bauer TW
PLoS One; 2013; 8(10):e77065. PubMed ID: 24204737
[TBL] [Abstract][Full Text] [Related]
19. SRC-3 inhibition blocks tumor growth of pancreatic ductal adenocarcinoma.
Song X; Chen H; Zhang C; Yu Y; Chen Z; Liang H; Van Buren G; McElhany AL; Fisher WE; Lonard DM; O'Malley BW; Wang J
Cancer Lett; 2019 Feb; 442():310-319. PubMed ID: 30423406
[TBL] [Abstract][Full Text] [Related]
20. Orthotopic and Heterotopic Murine Models of Pancreatic Cancer Exhibit Different Immunological Microenvironments and Different Responses to Immunotherapy.
Wang J; Liu X; Ji J; Luo J; Zhao Y; Zhou X; Zheng J; Guo M; Liu Y
Front Immunol; 2022; 13():863346. PubMed ID: 35874730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
